Note: The U.S. Food and Drug Administration (FDA) doesn’t approve supplements for safety or effectiveness. Always talk with your healthcare professional about whether a supplement fits your health ...

Forbes contributors publish independent expert analyses and insights. David Thomas Tao is an NYC-based spirits writer and media producer.

Jack Daniel’s Distillery Series is a collection of whiskeys that highlights the use of different mashbills, secondary maturations, and production methods, and is only available in limited numbers in ...

Hall of Fame quarterback Dan Marino recently revealed that he was diagnosed with metabolic dysfunction-associated steatohepatitis, or MASH. The Miami Dolphins legend said the discovery came years ago ...

There are two FDA-approved medications for the metabolic disorder known as MASH. Roche is paying $2.4 billion to acquire 89bio and its late-stage MASH drug, giving the Swiss pharmaceutical giant the ...

Roche dived into the metabolic dysfunction-associated steatohepatitis (MASH) space by agreeing to hand over up to $3.5 billion for 89bio and its phase-3-stage candidate for the fatty liver disease. At ...

NEW YORK, NEW YORK - JUNE 21: Dan Marino speaks onstage at Fanatics Fest NYC 2025 at Javits Center on June 21, 2025 in New York City. (Photo by Slaven Vlasic/Getty Images) To say that Dan Marino has ...

The whiskey delivers honey, burnt sugar, and smoky vanilla notes. Michter’s Distillery has announced the release of its US*1 Toasted Barrel Finish Sour Mash Whiskey. Set to arrive this September, the ...

Drug developers with products targeting a liver condition called metabolic dysfunction-associated steatohepatitis (MASH) traded higher on Wednesday after the U.S. FDA said it has accepted an ...

Tony Sachs has written for numerous publications about spirits and the people who make them since 2007, and traveled the globe to witness the processes firsthand. Michter’s has evolved from a defunct ...

The FDA expanded the indication for semaglutide (Wegovy) to treating adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), the agency announced. The glucagon-like peptide-1 ...

Targeting GLP-1 receptors now has the FDA’s blessing as a way to treat the fatty liver disease called MASH with Novo Nordisk’s weekly injectable drug Wegovy becoming the second approved treatment for ...